Clinical trial transparency and orphan drug development: recent trends in data sharing by the pharmaceutical industry.

Abstract

BACKGROUND Data sharing from clinical trials can be key to the development and approval of medicines for rare diseases. Many events during the first half of 2013 have contributed to the movement for increased transparency. These include the development of the European Medicines Agency's new data publication policy, the creation of the AllTrials petition and… (More)
DOI: 10.1159/000355941

Cite this paper

@article{So2013ClinicalTT, title={Clinical trial transparency and orphan drug development: recent trends in data sharing by the pharmaceutical industry.}, author={D. S. C. So and Yves Joly and B M Knoppers}, journal={Public health genomics}, year={2013}, volume={16 6}, pages={322-35} }